Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.

Tomoki Ito,Yoshinori Hashimoto,Yasuhiro Tanaka,Aya Nakaya,Shinya Fujita,Atsushi Satake,Takahisa Nakanishi,Akiko Konishi,Masaaki Hotta,Hideaki Yoshimura,Kazuyoshi Ishii,Akiko Hashimoto,Toshinori Kondo,Hiromi Omura,Isaku Shinzato,Takayuki Tanaka,Shosaku Nomura

Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.

2019

Tomoki Ito
Yoshinori Hashimoto
Yasuhiro Tanaka
Aya Nakaya
Shinya Fujita
Atsushi Satake
Takahisa Nakanishi
Akiko Konishi
Masaaki Hotta
Hideaki Yoshimura
Kazuyoshi Ishii
Akiko Hashimoto
Toshinori Kondo
Hiromi Omura
Isaku Shinzato
Takayuki Tanaka
Shosaku Nomura

Objective This study aimed to retrospectively assess the efficacy and safety of anagrelide in cytoreduction therapy‐naive essential thrombocythemia (ET) patients in a real‐world setting.

Keywords:

Immunology
Diabetes mellitus
Intensive care medicine
Anagrelide
Drug
Essential thrombocythemia
Medicine
Acute leukemia
Anemia
Myelofibrosis
Internal medicine
Cause of death
Adverse effect
Therapeutic effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations